<DOC>
	<DOCNO>NCT01010945</DOCNO>
	<brief_summary>This phase 1b study evaluate combination gemcitabine Tarceva ( erlotinib ) nab-paclitaxel patient advanced pancreatic cancer .</brief_summary>
	<brief_title>Erlotinib , Gemcitabine Nab-Paclitaxel Advanced Pancreatic Cancer</brief_title>
	<detailed_description>This single-arm , phase 1b study determine maximum tolerate dose ( MTD ) combination erlotinib ( daily ) , gemcitabine ( weekly ) , nab-paclitaxel ( weekly ) patient advanced pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 01 Predicted life expectancy &gt; = 12 week Previous surgery Histologically cytologically confirm , measurable , locally advanced , unresectable metastatic pancreatic adenocarcinoma No prior therapy pancreatic cancer Adequate organ marrow function Absolute neutrophil count &gt; = 1.5 x 10^9/L Platelets &gt; = 100 x 10^9/L Total bilirubin &lt; = institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) &lt; = 2 x institutional upper limit normal Serum creatinine &lt; = 1.5 x upper limit normal Negative pregnancy test Informed consent Patient must agree smoke study Significant history cardiac disease unless disease well control Active uncontrolled infection serious illness medical condition could interfere patient 's ongoing participation study History psychiatric condition might impair patient 's ability understand comply requirement study provide informed consent History smoking within previous 14 day enrollment positive cotinine test baseline Pregnant breastfeeding female Symptomatic brain metastasis stable , require steroid , potentially lifethreatening , require radiation within last 14 day History allergic reaction attribute compound similar chemical biological composition study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Advanced Pancreatic Cancer</keyword>
	<keyword>erlotinib</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>nab-paclitaxel</keyword>
	<keyword>Adenocarcinoma</keyword>
	<keyword>Phase 1b</keyword>
</DOC>